In addition to the MSI status, other potential biomarkers of ICIs include programmed cell death ligand 1 (PD-L1) expression, tumor mutation burden (TMB), and BRAF and KRAS gene mutation status (15), but their effects are not ideal. This evidence concerns the gene CD274 and neoplasm.